Semaglutide News and Research

Latest Semaglutide News and Research

TSRI scientists study 3-D structure of glucagon receptor for treatment of diabetes

The study is reported on July 17, 2013, in an advance online edition of the journal Nature, alongside a British laboratory's structural study of another member of the same class of receptors-known as "class B" G protein-coupled receptors (GPCRs).

18 Jul 2013

Coffee and appetite: an interview with Matt Schubert and Associate Professor Ben Desbrow, Griffith University

We wanted to do something a bit different than the “typical” work on caffeine and exercise, and I have considerable interest in appetite regulation, so we built up from there.

15 Jul 2013

UH and Case Western Reserve University to develop diagnostic tests to determine HIV drug resistance

Case Western Reserve University has signed an exclusive worldwide licensing agreement granting University Hospitals Case Medical Center rights to a series of diagnostic tests to determine drug resistance and co-receptor tropism in human immunodeficiency virus.

2 Jul 2013

Sanofi presents positive phase 3 data for GLP-1 receptor for type 2 diabetes

Sanofi US (EURONEXT: SAN and NYSE: SNY) announced today data that showed lixisenatide, an investigational once-daily prandial glucagon-like peptide 1 (GLP-1) receptor agonist, decreased HbA1c by reducing PPG (postprandial glucose) daytime exposure when added to standard of care which includes basal insulin with or without oral anti-diabetic agents (OADs). Lixisenatide is for the treatment of adults with type 2 diabetes mellitus.

24 Jun 2013

Researchers to study benefits, side effects of four widely used therapies in adults with type 2 diabetes

UT Southwestern Medical Center researchers are seeking 150 adults with type 2 diabetes to take part in the local arm of a major national clinical trial that will compare benefits and side effects of four widely used therapies to lower blood-sugar levels.

18 Jun 2013

Transition, Lilly amend agreement to address future development of TT-401

Transition Therapeutics Inc. announced that Eli Lilly and Company has exercised its option to assume all development and commercialization rights to type 2 diabetes drug candidate TT-401.

17 Jun 2013

NGM, MedImmune partner to develop novel therapeutics for treatment of diabetes and obesity

NGM Biopharmaceuticals, Inc. and MedImmune, the global biologics research and development arm of AstraZeneca, announced today that they have entered into an exclusive agreement to discover, develop and commercialize novel therapeutics from NGM's enteroendocrine cell program for the treatment of type 2 diabetes and obesity.

17 Jun 2013

Bristol-Myers Squibb, AstraZeneca release statement on ADA's efforts toward incretin-based therapies

Earlier this week, the American Diabetes Association called for manufacturers of incretin-based therapies to make patient-level data available from clinical trials for an independent analysis of pancreatic safety.

17 Jun 2013

New data on PROLOR Biotech's hGH-CTP and MOD-6030 to be presented at ENDO 2013

PROLOR Biotech, Inc., today announced that the company will present new data on its long-acting human growth hormone (hGH-CTP) in Phase III development for the treatment of growth hormone deficiency and its long acting oxyntomodulin (MOD-6030) in preclinical development for the treatment of obesity and type 2 diabetes at ENDO 2013, the 95th Annual Meeting of the Endocrine Society.

13 Jun 2013

Drug regulators slow to pursue concerns about potential adverse effects of new diabetes drugs

The BMJ and Channel 4 Dispatches investigated and found that evidence suggesting potential harm from the drugs in industry studies has not been published.

10 Jun 2013

Baylor Endocrine Center seeks volunteers to compare long-term benefits and risks of diabetes drugs

Baylor Endocrine Center is looking for volunteers to take part in a study to compare the long-term benefits and risks of four widely used diabetes drugs in combination with metformin, the most common first-line medication for treating type 2 diabetes. The project is called the GRADE: Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study.

4 Jun 2013

Newer class of diabetes medications may also improve cardiovascular health, researchers report

A newer class of medications used to control blood sugar levels in type 2 diabetics may also improve cardiovascular health, researchers from The Ohio State University Wexner Medical Center reported in a new meta-analysis presented yesterday at the American Society of Hypertension's Annual Scientific Meeting and Exposition.

17 May 2013

Lexicon Pharmaceuticals advances Phase 2 clinical trial of LX4211 in patients with type 1 diabetes

Lexicon Pharmaceuticals, Inc. announced today that it is progressing into the placebo-controlled portion of its Phase 2 clinical trial of LX4211 in patients with type 1 diabetes, having successfully completed the open-label, pioneer portion of the trial.

10 May 2013

Phase 1b clinical study data of EBI-005 for treatment of dry eye disease presented at ARVO meeting

Eleven Biotherapeutics, a biopharmaceutical company designing and engineering novel and differentiated protein-based biotherapeutics for ocular diseases, announced today the presentation of data for EBI-005, the first IL-1 (Interleukin-1) signaling inhibitor designed for topical ocular administration, at the Association for Research in Vision and Ophthalmology 2013 Annual Meeting in Seattle, Washington.

9 May 2013

EPAC2 and diabetes: an interview with Dr. Hussain, Johns Hopkins University

EPAC stands for exchange protein activated by cyclic AMP (cAMP). cAMP is an (among many) intracellular messenger molecule. cAMP is generated when certain hormones stimulate a cell by binding to their receptor, which is at the outside surface of the cell.

3 May 2013

Pancreatitis and diabetes drugs: an interview with Dr Sonal Singh, Johns Hopkins University School of Medicine

Acute pancreatitis is an inflammation of the pancreas which leads to leakage of pancreatic enzymes. Apart from certain drugs such as GLP-1 based therapies, the most common causes of pancreatitis are Gallstones and Alcohol use.

30 Apr 2013

Eli Lilly reports positive results from Phase III AWARD trials of type 2 diabetes drug, dulaglutide

Eli Lilly and Company today announced positive top-line results of two additional Phase III AWARD trials for dulaglutide, an investigational, long-acting glucagon-like peptide 1 (GLP-1) receptor agonist being studied as a once-weekly treatment for type 2 diabetes.

18 Apr 2013

New study associates commonly used diabetes drugs with pancreatic cancer risk

ndividuals who had taken a type of drug commonly used to treat Type 2 diabetes showed abnormalities in the pancreas, including cell proliferation, that may be associated with an increased risk of neuroendocrine tumors, according to a new study by researchers from UCLA and the University of Florida.

28 Mar 2013

GLP1 medications appear to protect diabetic patients from heart failure

A class of medications commonly prescribed to lower blood sugar in diabetic patients appears to protect them from developing heart failure, according to a study at Henry Ford Hospital in Detroit.

11 Mar 2013

GLP-1 pancreatitis concerns justified

Study results have raised further concerns over a link between pancreatitis and the use of glucagon-like peptide-1 (GLP-1)-based therapies for patients with Type 2 diabetes.

28 Feb 2013

Semaglutide News and Research

Latest Semaglutide News and Research

TSRI scientists study 3-D structure of glucagon receptor for treatment of diabetes

Coffee and appetite: an interview with Matt Schubert and Associate Professor Ben Desbrow, Griffith University

UH and Case Western Reserve University to develop diagnostic tests to determine HIV drug resistance

Sanofi presents positive phase 3 data for GLP-1 receptor for type 2 diabetes

Researchers to study benefits, side effects of four widely used therapies in adults with type 2 diabetes

Transition, Lilly amend agreement to address future development of TT-401

NGM, MedImmune partner to develop novel therapeutics for treatment of diabetes and obesity

Bristol-Myers Squibb, AstraZeneca release statement on ADA's efforts toward incretin-based therapies

New data on PROLOR Biotech's hGH-CTP and MOD-6030 to be presented at ENDO 2013

Drug regulators slow to pursue concerns about potential adverse effects of new diabetes drugs

Baylor Endocrine Center seeks volunteers to compare long-term benefits and risks of diabetes drugs

Newer class of diabetes medications may also improve cardiovascular health, researchers report

Lexicon Pharmaceuticals advances Phase 2 clinical trial of LX4211 in patients with type 1 diabetes

Phase 1b clinical study data of EBI-005 for treatment of dry eye disease presented at ARVO meeting

EPAC2 and diabetes: an interview with Dr. Hussain, Johns Hopkins University

Pancreatitis and diabetes drugs: an interview with Dr Sonal Singh, Johns Hopkins University School of Medicine

Eli Lilly reports positive results from Phase III AWARD trials of type 2 diabetes drug, dulaglutide

New study associates commonly used diabetes drugs with pancreatic cancer risk

GLP1 medications appear to protect diabetic patients from heart failure

GLP-1 pancreatitis concerns justified

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Semaglutide News and Research

Latest Semaglutide News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in